Clinical Trial Update: Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial of tislelizumab combined with fruquintinib for metastatic pMMR/MSS colorectal cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Metastatic Colorectal Cancer, mCRC | Phase 2 | Status: WITHDRAWN